← Eichor
Study identifier: NCT06351475 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

Condition: Peritoneal Neoplasms · Hyperthermic Intraperitoneal Chemotherapy · Intraoperative Care  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants140
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day. Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial. Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Inf…

This description comes directly from the study's public registry record.

Talk to the study team

Arthur Moreau, Dr  ·  142499394  ·  arthur.moreau@aphp.fr

Jérôme Lambert, Pr  ·  142499742  ·  jerome.lambert@u-paris.fr

Always discuss trial participation with your own doctor first.

Locations (7)

Institut régional du Cancer de MontpellierMontpellier, FranceRecruiting
La Pitié Salpetriere hospitalParis, FranceRecruiting
Lariboisière hospitalParis, FranceRecruiting
Saint Louis hospitalParis, FranceRecruiting
Robert Debré hospitalReims, FranceRecruiting
Hôpital Hautepierre / UIC ARMOStrasbourg, FranceRecruiting
Gustave Roussy InstituteVillejuif, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06351475